B-cell proliferation potential assessed at a single cell level
| Groups . | % BrdU+ B cells . | |
|---|---|---|
| Anti-IgM . | LPS . | |
| Normal C57BL/6 | 30.5 ± 1.8 | 26.6 ± 3.4 |
| Syngeneic full-term fetal blood | 35.2 ± 6.6 | 31.1 ± 1.1 |
| Allogeneic T-cell–depleted bone marrow | 34.8 ± 5.3 | 33.0 ± 4.2 |
| Allogeneic full-term fetal blood | 22.5 ± 1.03-150 | 23.7 ± 1.23-150 |
| Groups . | % BrdU+ B cells . | |
|---|---|---|
| Anti-IgM . | LPS . | |
| Normal C57BL/6 | 30.5 ± 1.8 | 26.6 ± 3.4 |
| Syngeneic full-term fetal blood | 35.2 ± 6.6 | 31.1 ± 1.1 |
| Allogeneic T-cell–depleted bone marrow | 34.8 ± 5.3 | 33.0 ± 4.2 |
| Allogeneic full-term fetal blood | 22.5 ± 1.03-150 | 23.7 ± 1.23-150 |
Spleen cells were obtained 200 days after transplantation and activated by anti-IgM antibody and LPS. Proliferation of B cells was determined by incorporation of BrdU on B cells, which was measured by intracellular fluorescent detection of BrdU staining combined with B220 surface staining.
P < .05, compared with other groups.